President Vladimir Putin has officially greenlit an ambitious national scientific project aimed at reversing the biological clock, directing a team of the country’s top geneticists and biotechs to develop a groundbreaking “anti-aging vaccine.”

The initiative, operating under the formal title of the “New Technologies for Health Preservation” project, has been allocated a massive budget of more than 2 trillion rubles, approximately $26.4 billion, signaling the Kremlin’s shift toward longevity as a primary pillar of national security.

The centerpiece of this research is a gene therapy drug designed to target and block the RAGE receptor, a specific cellular component that scientists identify as a primary trigger for the aging process in human cells. According to Deputy Science and Higher Education Minister Denis Sekirinsky, the goal is to create the world’s first treatment capable of slowing down cellular decay. “The activation of the RAGE gene launches the aging of the cell,” Sekirinsky stated during a recent longevity conference. “Blocking it, conversely, can prolong its youth.”

The project is being spearheaded by the Institute of Aging Biology and Medicine in collaboration with the prestigious Kurchatov Institute. Insiders suggest the project is heavily influenced by Mikhail Kovalchuk, a physicist and close confidant of the President, who has long advocated for research into the “Russian genome” and life extension.

The government has set an aggressive timeline, with Deputy Prime Minister Tatyana Golikova indicating that mass production of anti-aging biomedical products could begin between 2028 and 2030.

While the Kremlin frames the project as a solution to Russia’s demographic decline and a way to increase healthy life expectancy to 78 years by 2030, the move has drawn sharp criticism from the international medical community. Skeptics point to the irony of spending billions on “immortality” research while the Russian federal budget simultaneously slashes funding for primary healthcare, emergency services, and diabetes treatments by more than half to sustain the ongoing conflict in Ukraine.

Despite the controversy, the directive remains a top priority for the Russian Health Ministry. Scientists have been ordered to “urgently” submit proposals for technologies that combat cognitive decline, prevent tissue atrophy, and utilize advanced bioprinting to replace aging organs. As the project moves into its active phase in 2026, it represents one of the most well-funded and most secretive scientific endeavors in modern Russian history.